S208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL

Documenti analoghi

• The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
  di: Andrew D. Zelenetz, et al.
  Pubblicazione: (2024-08-01)
• P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY
  di: J. D. Soumerai, et al.
  Pubblicazione: (2022-06-01)
• P1086: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE
  di: Takahiro Kumode, et al.
  Pubblicazione: (2023-08-01)
• miR-208a in Cardiac Hypertrophy and Remodeling
  di: Xing-Huai Huang, et al.
  Pubblicazione: (2021-12-01)
• MiR 208a Regulates Mitochondrial Biogenesis in Metabolically Challenged Cardiomyocytes
  di: Naveen Mekala, et al.
  Pubblicazione: (2021-11-01)